In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), B Group, Inc. reported 20 stock positions worth $134.9 million . Its top holding was Adma Biologics (ADMA) at 21.4% of the portfolio, followed by Palisade Bio (PALI, 14.8% ) and Praxis Precision Medicines I (PRAX, 7.9% ). Compared with Q4 2025, it opened 5 new positions, added to 6 and reduced 1. The biggest buy was Palisade Bio (PALI, shares +154% ) and the biggest sale Apogee Therapeutics (APGE, shares −63% ).
Location DALLAS, TX
CIK 0002043476
Portfolio Value $134.9M (Q1 2026) Holdings 20 stocks · $134.9M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2025 ADMA Adma Biologics Inc. 3,207,542 $28.9M Add +30.5% PALI Palisade Bio Inc. 11,414,285 $20.0M Add +153.7% PRAX Praxis Precision Medicines I 33,237 $10.7M No change CLLS Cellectis - ADR 3,281,501 $10.4M No change ZLAB Zai Lab Ltd.-ADR 450,646 $8.5M Add +12.7% TSHA Taysha Gene Therapies Inc. 1,800,556 $8.0M No change NRXP NRX Pharmaceuticals Inc. 3,000,000 $6.4M New GPCR Structure Therapeutics Inc. 127,500 $6.1M Add +41.7% IOVA Iovance Biotherapeutics Inc. 1,500,000 $5.3M No change SYRE Spyre Therapeutics Inc. 100,000 $5.0M No change DRUG Bright Minds Biosciences Inc. 67,500 $4.9M New ASMB Assembly Biosciences Inc. 175,706 $4.9M No change AURA Aura Biosciences Inc. 597,576 $4.0M Add +4.4% ORKA Oruka Therapeutics Inc. 75,000 $3.7M No change SGHT Sight Sciences Inc. 970,000 $3.7M Add +5.4% RARE Ultragenyx Pharmaceutical Inc. 135,000 $2.8M No change APGE Apogee Therapeutics Inc. 7,500 $631K Reduce -62.5% FHTX Foghorn Therapeutics Inc. 102,000 $488K New SLNO Soleno Therapeutics Inc. 7,500 $251K New REPL Replimune Group Inc. 26,000 $199K New
Portfolio Sells Q4 2025 → Q1 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▲ APGE Apogee Therapeutics Inc. Reduce -62.5% 0.47% −0.65
Portfolio Buys Q4 2025 → Q1 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▼ PALI Palisade Bio Inc. Add +153.7% 14.81% +6.97 NRXP NRX Pharmaceuticals Inc. New 4.74% +4.74 DRUG Bright Minds Biosciences Inc. New 3.65% +3.65 ZLAB Zai Lab Ltd.-ADR Add +12.7% 6.28% +1.06 AURA Aura Biosciences Inc. Add +4.4% 2.96% +0.65 FHTX Foghorn Therapeutics Inc. New 0.36% +0.36 SLNO Soleno Therapeutics Inc. New 0.19% +0.19 REPL Replimune Group Inc. New 0.15% +0.15 GPCR Structure Therapeutics Inc. Add +41.7% 4.56% −0.08 SGHT Sight Sciences Inc. Add +5.4% 2.71% −2.70 ADMA Adma Biologics Inc. Add +30.5% 21.43% −11.79
Options Activity Q4 2025 → Q1 2026 Security Type Change vs Q4 2025 Underlying Shares Value ▼ REPL Replimune Group Inc. call Sold out 50,000 $486Kbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 18 $176.2M ADMA, PALI, NRXP, FTH, TSHA Q1 2026 20 $134.9M ADMA, PALI, PRAX, CLLS, ZLAB Q4 2025 15 $134.9M ADMA, CLLS, PALI, TSHA, PRAX Q3 2025 16 $100.1M ADMA, ZLAB, AKRO, CLLS, TSHA Q2 2025 15 $115.8M ADMA, INSM, ZLAB, AKRO, CLLS Q1 2025 17 $115.1M ADMA, INSM, ZLAB, AKRO, IOVA Q4 2024 18 $163.6M INVESCO QQQ TR, ADMA, INSM, ZLAB, IOVA